Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05733598
Title RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Replimune Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.